Inhaled interferon and diffusion capacity in idiopathic pulmonary fibrosis (IPF)

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 32, Issue 1, 2015, Pages 37-42

  Skaria, S D ^a   Yang, Jie ^a   Condos, Rany ^b   Smaldone, G C ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Aerosol; Clinical endpoint; Pulmonary function testing

Indexed keywords

GAMMA1B INTERFERON; PIRFENIDONE; PLACEBO; GAMMA INTERFERON; PYRIDONE DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; FUNCTIONAL RESIDUAL CAPACITY; HOME NEBULIZER; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESIDUAL VOLUME; TOTAL LUNG CAPACITY; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; IDIOPATHIC PULMONARY FIBROSIS; INHALATIONAL DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MORTALITY; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; REFERENCE VALUE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERFERON-GAMMA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PULMONARY DIFFUSING CAPACITY; PYRIDONES; RECOMBINANT PROTEINS; REFERENCE VALUES; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84937547067     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6):788-824.
2. King TE, Jr., Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949-1961.
3. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. The New England journal of medicine. 1999;341(17):1264-1269.
4. Ziesche R, Block LH. [The lung as an immunologic organ]. Wien Klin Wochenschr. 1999;111 Suppl 1:1-5.
5. Sime PJ, O'Reilly KM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol. 2001;99(3):308-319.
6. Gauldie J, Kolb M, Sime PJ. A new direction in the pathogenesis of idiopathic pulmonary fibrosis? Respir Res. 2002;3:1.
7. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(4):459-466.
8. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011; 183(9):1231-1237.
9. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184(12):1382-1389.
10. Luppi F, Losi M, D'Amico R, Fabbri LM, Richeldi L. Endogenous blood maximal interferon-gamma production may predict response to interferon-gamma 1beta treatment in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(1):64-68.
11. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760-1769.
12. Diaz KT, Skaria S, Harris K, et al. Delivery and safety of inhaled interferon-gamma in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv. 2012;25(2):79-87.
13. Giri SN. Novel pharmacological approaches to manage interstitial lung fibrosis in the twenty-first century. Annu Rev Pharmacol Toxicol. 2003;43:73-95.
14. Strieter RM, Starko KM, Enelow RI, Noth I, Valentine VG. Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2004;170(2):133-140.
15. Antoniou KM, Nicholson AG, Dimadi M, et al. Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. The European respiratory journal. 2006;28(3):496-504.
16. King TE, Jr., Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009;374(9685):222-228.
17. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. The New England journal of medicine. 2004;350(2):125-133.
18. Thomeer M, Grutters JC, Wuyts WA, Willems S, Demedts MG. Clinical use of biomarkers of survival in pulmonary fibrosis. Respir Res. 2010;11:89.
19. King TE, Albera C, Bradford WZ, et al. All-cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis: Implications for the Design and Execution of Clinical Trials. Am J Respir Crit Care Med. 2014;in press, Published on 29-January-2014.
20. Woodcock HV, Mahr TM. The treatment of idiopathic pulmonary fibrosis. F1000Prime Reports. 2014;6(16):6-16.
21. Hanson D, Winterbauer RH, Kirtland SH, Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest. 1995;108(2):305-310.
22. Collard HR, King TE, Jr., Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168(5):538-542.
23. Folcik VA, Garofalo M, Coleman J, et al. Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2013.